Certara, Inc. (NASDAQ:CERT) Stock Rated “Hold” by Sell-Side Brokerages

Shares of Certara, Inc. (NASDAQ:CERT) have been assigned an average rating of “Hold” from the twelve analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $9.18.

A number of equities analysts have recently commented on CERT shares. TD Cowen raised their price objective on shares of Certara from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Weiss Ratings lowered shares of Certara from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. Barclays increased their target price on shares of Certara from $7.50 to $9.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. UBS Group reiterated a “neutral” rating and issued a $10.00 target price on shares of Certara in a research note on Wednesday, September 30th. Finally, KeyCorp raised their price target on shares of Certara from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Friday.

Certara Stock Up 0.9%

CERT stock opened at $9.45 on Tuesday. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $1.44 billion, a PE ratio of -21.00 and a beta of 1.42. Certara has a twelve month low of $4.45 and a twelve month high of $12.94. The stock has a 50-day simple moving average of $8.57 and a two-hundred day simple moving average of $7.01.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The company had revenue of $93.27 million for the quarter, compared to the consensus estimate of $98.09 million. During the same quarter in the prior year, the company earned $0.07 earnings per share. The company’s quarterly revenue was down 10.8% on a year-over-year basis. On average, equities analysts predict that Certara will post 0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Certara

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Certara during the second quarter worth about $123,259,000. Haveli Investment Management LLC bought a new position in Certara in the 2nd quarter worth about $48,470,000. Jefferies Financial Group Inc. bought a new position in Certara in the 2nd quarter worth about $46,446,000. Bank of America Corp DE bought a new position in Certara in the 2nd quarter worth about $11,780,000. Finally, Tejara Capital Ltd purchased a new stake in shares of Certara in the 2nd quarter valued at about $8,467,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc (NASDAQ:CERT) provides software and technology-enabled services for the biopharmaceutical industry. The company helps drug developers use regulatory science, data analysis, and modeling and simulation to support decisions throughout the research, development, and commercialization lifecycle.

Its offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial design, patient and disease modeling, regulatory submissions, and real-world data analysis.